@article{4c3606aca41344a7b70db2974a9e69f1,
title = "The diagnosis and management of anaphylaxis practice parameter: 2010 Update",
abstract = "These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing {"}The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update.{"} This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, or the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.",
keywords = "Anaphylaxis, drug allergy, exercise anaphylaxis, food allergy, intraoperative anaphylaxis, latex allergy",
author = "Phillip Lieberman and Nicklas, {Richard A.} and John Oppenheimer and Kemp, {Stephen F.} and Lang, {David M.} and Bernstein, {David I.} and Bernstein, {Jonathan A.} and Burks, {A. Wesley} and Feldweg, {Anna M.} and Fink, {Jordan N.} and Greenberger, {Paul A.} and Golden, {David B K} and James, {John M.} and Ledford, {Dennis K.} and Sheffer, {Albert L.} and Joann Blessing-Moore and Linda Cox and Khan, {David A.} and Portnoy, {Jay M.} and Christopher Randolph and Schuller, {Diane E.} and Spector, {Sheldon L.} and Stephen Tilles and Dana Wallace",
note = "Funding Information: Disclosure of potential conflict of interest: P. Lieberman is a consultant for Dey, Sanofi, Aventis, and Intelliject. SF Kemp is a consultant for Sciele Pharma Inc. J. Oppenheimer has received research support from AstraZeneca, Boehringer Ingelheim, Schering Plough, Merck, Novartis, and GlaxoSmithKline ; has provided expert medical defense in legal cases; and is on the Board of Directors of ABAI. D. M. Lang is a consultant and speaker for GlaxoSmithKline; is a speaker for AstraZeneca, Sanofi-Aventis, and Novartis; and has received research support from Novartis and GlaxoSmithKline . D. I. Bernstein has received research support from the ACAAI Collaborative Study . JA Bernstein is Editor of the Journal of Asthma; is a consultant for Dynova Labs; is an Immunology Consultant for Flint Hills Resources; has received research support from Dyax, Shire, BI, CSL Behring, and Virapharm ; is President of the Cincinnati Allergy Society; and is AAAAI EORD interest section chair. A. W. Burks is a consultant for ActoGeniX NV, Intelliject, McNeil Nutritionals, and Schering-Plough; is a minority stockholder in Allertein and Mast Cell Inc; is on the Advisory Board for Dannon Co Probiotics; is on the Expert Panel for Schering-Plough; has received research support from the National Institutes of Health, Food Allergy and Anaphylaxis Network, and Wallace Research Foundation ; has provided expert witness testimony on the topic of food allergy; is on the Medical Board of Directors for FAAN; is a Dermatological Allergy Committee Member for ACAAI; is a Study Section Member of the NIH HAI; and is on the Reviewer Board for the JACI and FDA. J. N. Fink has provided expert witness testimony on the topic of mold allergy. P. A. Greenberger is an AAAAI past president; and has provided expert witness testimony on the topics of allergic bronchopulmonary aspergillosis and fatal food anaphylaxis. D. B. K. Golden is on the Speakers Bureau for ALK-Abello and Novartis-Genentech. J. M. James is a Board Member of the American Board of Allergy and Immunology and the Food Allergy and Anaphylaxis Network. D. K. Ledford is on the Speakers Bureau for AstraZeneca and Merck; is a consultant for We Care Health Care Clinics; has received research support from Genentech, Forest Pharmaceuticals, and Boehringer Ingelheim ; is on the Board of Directors for the American Academy of Allergy, Asthma, and Immunology; is an Associate Editor of the Journal of Allergy and Clinical Immunology and Allergy Report. J. Blessing-Moore is on the Speakers Bureau for AstraZeneca, Merck, and Novartis L Cox is on the AAAAI Board of Directors. D. A. Khan is a speaker for AstraZeneca and Merck; has received research support from the Vanberg Family Foundation, and Sellars Family Foundation ; is Conjoint Board Review Chair for ACAAI; and a past president of TAAIS. S. Spector is a consultant for Abbott, AstraZeneca, Genentech, Sanofi-Aventis, Schering-Plough, Medpoint, and Sepracor; is on the Advisory Board for Abbott, AstraZeneca, Genentech, Johnson 7 Johnson, Novartis, Schering-Plough, Skypharma, Merck, and Sepracor; is a speaker for AstraZeneca, Genentech, Sanofi-Aventis, Schering-Plough, Merck, and Sepracor; and has received research support from Abbott, Accentia, Amgen, Altana, AstraZeneca, Boehringer-Ingelheim, CTI Inc, Eli-Lilly, Genentech, GlaxoSmithKline, Idec, IgPro, Johnson & Johnson, Novartis, Ono Pharma, Sanofi-Aventis, Schering Plough, Skypharma, Synta, Merck, Medpoint, and Sepracor . S. Tilles is a consultant of Merck, ALK, and Ista; is a speaker for Alcon; and is Associate Editor for ACAAI AllergyWatch and the Annals of Allergy. The rest of the authors have declared that they have no conflicts of interest. ",
year = "2010",
month = sep,
doi = "10.1016/j.jaci.2010.06.022",
language = "English (US)",
volume = "126",
pages = "477--480+e1--e42",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",
}